Cover Image
市場調查報告書

血漿療法的全球市場預測 2021年:純PRP療法、多白血球PRP療法、純多血小板纖維蛋白療法、多白血球纖維蛋白療法

Plasma Therapy Market by Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin), Source (Autologous, Allogenic), Application (Orthopedic, Dermatology, Cardiac Muscle Injury), End User, Region - Global Forecast to 2021

出版商 MarketsandMarkets 商品編碼 364559
出版日期 內容資訊 英文 212 Pages
訂單完成後即時交付
價格
Back to Top
血漿療法的全球市場預測 2021年:純PRP療法、多白血球PRP療法、純多血小板纖維蛋白療法、多白血球纖維蛋白療法 Plasma Therapy Market by Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin), Source (Autologous, Allogenic), Application (Orthopedic, Dermatology, Cardiac Muscle Injury), End User, Region - Global Forecast to 2021
出版日期: 2016年07月22日 內容資訊: 英文 212 Pages
簡介

全球血漿療法市場規模預計從2016年到2021年以14.0%的年複合成長率擴大,從2016年的1億3560萬美元到2021年達到2億9,760萬美元。各市場區隔中,純PRP (多血小板血漿) 療法在預測期間內以最高年複合成長率成長。

本報告提供全球血漿療法市場相關分析,市場基本結構和最新趨勢,主要市場促進、阻礙因素,市場規模趨勢預測,各類型、來源、應用、終端用戶、地區的詳細趨勢,市場競爭的狀態,今後的市場發展的方向性,主要企業簡介等調查、考察。

第1章 簡介、調查手法

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 全球血漿療法市場上富有魅力的機會
  • 血漿療法市場上目前趨勢

第5章 血漿療法的全球市場:概要

  • 簡介
  • 市場區隔
    • 各類型
    • 各來源
    • 各應用領域
    • 各終端用戶
  • 市場動態

第6章 血漿療法的全球市場:各類型

  • 簡介
  • 純多血小板血漿 (PRP) 療法
  • 多白血球PRP療法
  • 純多血小板纖維蛋白 (PRF) 療法
  • 多白血球纖維蛋白療法

第7章 血漿療法市場:各來源

  • 簡介
    • 自我輸血
    • 同種異體

第8章 血漿療法的全球市場:各應用領域

  • 簡介
  • 整形外科
    • 風濕
    • 慢性肌腱炎
    • 骨骼修復、再生
  • 皮膚科
    • 雄性脫毛症
    • 美容整形
  • 心肌損傷
  • 牙科
  • 神經損傷
  • 其他

第9章 血漿療法的全球市場:各終端用戶

  • 簡介
  • 醫院、診療所
  • 研究機關

第10章 血漿療法的全球市場:各地區

  • 簡介
  • 北美
    • 市場競爭
    • 美國、加拿大的血漿療法市場短期的、中期的、長期性的成長
    • 各類型
    • 各來源
    • 各應用領域
    • 各終端用戶
    • 美國
    • 加拿大
  • 歐洲
    • 簡介
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 其他的歐洲 (RoE)
  • 亞太地區
    • 簡介
    • 各類型
    • 各來源
    • 各應用領域
    • 各終端用戶
    • 各國
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 韓國
    • 其他的亞太地區
  • 其他 (RoW)
    • 各類型
    • 各來源
    • 各應用領域
    • 各終端用戶

第11章 競爭情形

  • 概要
  • 市場佔有率分析
  • 競爭情形、趨勢

第12章 企業簡介

  • BIOLIFE PLASMA SERVICES
  • CAMBRYN BIOLOGICS LLC
  • BIOTEST
  • CSL LTD.
  • GRIFOLS INTERNATIONAL S.A.
  • KEDRION S.P.A.
  • LFB SA
  • BIO PRODUCT LABORATORY LTD. (BPL)
  • CHINA BIOLOGIC PRODUCTS, INC.
  • OCTAPHARMA
  • ■圖表清單
目錄
Product Code: BT 4457

The plasma therapy market is expected to grow from USD 135.6 million in 2016 to USD 297.6 million by 2021, at a CAGR of 14.0% from 2016 to 2021. This market is segmented on the basis of type, source, application, end user, and region. The pure PRP segment of the plasma therapy type market is expected to grow at the highest CAGR during the forecast period. Growth in this segment is mainly attributed to the high success rate of pure PRP therapy, less recovery time, and increase in healthcare expenditure worldwide.

Based on source, the plasma therapy market is segmented into autologous and allogenic. The autologous source segment is estimated to account for the largest share of the plasma therapy market in 2016. Prevalence of orthopedic disorders and the need for development of new therapies will drive the growth of this segment.

Based on application, the plasma therapy market is segmented into dermatology, cardiac muscle injury, dental, nerve injury, and others. The orthopedic segment is further segmented into arthritis, chronic tendinitis, and bone repair & regeneration. Similarly, the dermatology segment is further segmented into androgenic alopecia and plastic surgery. The dermatology application segment is expected to grow at the highest CAGR from 2016 to 2021, owing to increase in the number of cosmetic procedures and prevalence of dermatological disorders such as androgenic alopecia.

Based on end user, the plasma therapy market is segmented into hospitals & clinics and research institutes. The hospitals & clinics segment is estimated to account for the largest share of the global plasma therapy market in 2016. Rise in healthcare spending has resulted in the increasing use of PRP in hospitals & clinics.

On the basis of region, the plasma therapy market is led by North America, followed by Europe, Asia-Pacific, and rest of the world. Major factors contributing to the growth of the plasma therapy market include high incidences of trauma, increase in healthcare expenditure, and access to medical insurance in the U.S. On the other hand, stringent regulatory policies and side-effects associated with PRP therapy are restraining the growth of this market.

The report provides a competitive landscape that covers growth strategies adopted by industry players over the last three years. In addition to this, the report also offers an overview of company profiles that comprise product portfolios, developments, and strategies adopted by market players to maintain and increase their shares in the market. The market research data, current market size, and forecast of the future trends will help key market players and new entrants to make necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to maintain their competitive position in the plasma therapy market.

Major players operating in the plasma therapy market include BioLife Plasma Services (U.S.), Cambryn Biologics LLC (U.S.), Biotest (Germany), CSL Ltd. (Australia), Grifols International S.A. (Spain), Kedrion S.p.A. (Italy), LFB (France), Bio Products Laboratory Ltd. (BPL) (U.K.), China Biologic Products, Inc. (China), and Octapharma (Switzerland).

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below mentioned strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product portfolios of top players in the plasma therapy market. The report analyzes the plasma therapy market on the basis of type, source, application, end user, and region.
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the plasma therapy market.
  • Competitive Assessment: In-depth assessment of market strategies, geographic and business segments, and product portfolios of leading players in the plasma therapy market.
  • Market Development: Comprehensive information about emerging markets; this report analyzes the market for various plasma therapy products across varied geographies.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the plasma therapy market.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. KEY DATA FROM SECONDARY SOURCES
    • 2.1.2. KEY DATA FROM PRIMARY SOURCES
      • 2.1.2.1. Breakdown of primary interview
  • 2.2. MARKET SIZE ESTIMATION
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. RESEARCH ASSUMPTIONS

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. ATTRACTIVE OPPORTUNITIES IN THE GLOBAL PLASMA THERAPY MARKET
  • 4.2. CURRENT TRENDS IN THE PLASMA THERAPY MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
    • 5.2.1. PLASMA THERAPY MARKET, BY TYPE
    • 5.2.2. PLASMA THERAPY MARKET, BY SOURCE
    • 5.2.3. PLASMA THERAPY MARKET, BY APPLICATION
    • 5.2.4. PLASMA THERAPY MARKET, BY END USER
  • 5.3. MARKET DYNAMICS
    • 5.3.1. MARKET DRIVERS
      • 5.3.1.1. Rising incidences of sports injuries
      • 5.3.1.2. Increase in the number of androgenic alopecia patients worldwide
      • 5.3.1.3. Growing use of platelet-rich plasma in various therapeutic areas
      • 5.3.1.4. Prevalence of arthritis
    • 5.3.2. MARKET RESTRAINTS
      • 5.3.2.1. Lack of reimbursement policies
      • 5.3.2.2. Varying prices of plasma therapy
    • 5.3.3. MARKET OPPORTUNITIES
      • 5.3.3.1. Increase in the number of patients suffering from orthopedic disorders and androgenic alopecia
    • 5.3.4. MARKET CHALLENGES
      • 5.3.4.1. Restricted use of PRP in patients suffering from diabetes and kidney ailments
      • 5.3.4.2. Developments in other fields of regenerative medicine

6. PLASMA THERAPY MARKET, BY TYPE

  • 6.1. INTRODUCTION
  • 6.2. PURE PRP
  • 6.3. LEUKOCYTE-RICH PRP
  • 6.4. PURE PLATELET-RICH FIBRIN
  • 6.5. LEUKOCYTE-RICH FIBRIN

7. PLASMA THERAPY MARKET, BY SOURCE

  • 7.1. INTRODUCTION
    • 7.1.1. AUTOLOGOUS
    • 7.1.2. ALLOGENIC

8. PLASMA THERAPY MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. ORTHOPEDIC
    • 8.2.1. ARTHRITIS
    • 8.2.2. CHRONIC TENDINITIS
    • 8.2.3. BONE REPAIR & REGENERATION
  • 8.3. DERMATOLOGY
    • 8.3.1. ANDROGENIC ALOPECIA
    • 8.3.2. PLASTIC SURGERY
  • 8.4. CARDIAC MUSCLE INJURY
  • 8.5. DENTAL
  • 8.6. NERVE INJURY
  • 8.7. OTHERS

9. PLASMA THERAPY MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. HOSPITALS & CLINICS
  • 9.3. RESEARCH INSTITUTES

10. PLASMA THERAPY MARKET, BY GEOGRAPHY

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. COMPETITION IN NORTH AMERICA PLASMA THERAPY MARKET
    • 10.2.2. NEAR-TERM, MID-TERM, AND LONG-TERM GROWTH OF THE PLASMA THERAPY MARKET IN U.S. AND CANADA
    • 10.2.3. NORTH AMERICA PLASMA THERAPY MARKET, BY TYPE
    • 10.2.4. NORTH AMERICA PLASMA THERAPY MARKET, BY SOURCE
    • 10.2.5. NORTH AMERICA PLASMA THERAPY MARKET, BY APPLICATION
    • 10.2.6. NORTH AMERICA PLASMA THERAPY MARKET, BY END USER
    • 10.2.7. U.S.
      • 10.2.7.1. U.S. PLASMA THERAPY MARKET OVERVIEW
      • 10.2.7.2. U.S. PLASMA THERAPY MARKET, BY TYPE
      • 10.2.7.3. U.S. PLASMA THERAPY MARKET, BY SOURCE
      • 10.2.7.4. U.S. PLASMA THERAPY MARKET, BY APPLICATION
      • 10.2.7.5. U.S. PLASMA THERAPY MARKET, BY END USER
    • 10.2.8. CANADA
      • 10.2.8.1. CANADA PLASMA THERAPY MARKET OVERVIEW
      • 10.2.8.2. CANADA PLASMA THERAPY MARKET, BY TYPE
      • 10.2.8.3. CANADA PLASMA THERAPY MARKET, BY SOURCE
      • 10.2.8.4. CANADA PLASMA THERAPY MARKET, BY APPLICATION
      • 10.2.8.5. CANADA PLASMA THERAPY MARKET, BY END USER
  • 10.3. EUROPE
    • 10.3.1. INTRODUCTION
      • 10.3.1.1. COMPETITION IN THE EUROPE PLASMA THERAPY MARKET
      • 10.3.1.2. NEAR-TERM, MID-TERM, AND LONG-TERM GROWTH OF THE PLASMA THERAPY MARKET IN EUROPE
      • 10.3.1.3. EUROPE PLASMA THERAPY MARKET, BY TYPE
      • 10.3.1.4. EUROPE PLASMA THERAPY MARKET, BY SOURCE
      • 10.3.1.5. EUROPE PLASMA THERAPY MARKET, BY APPLICATION
      • 10.3.1.6. EUROPE PLASMA THERAPY MARKET, BY END USER
      • 10.3.1.7. EUROPE PLASMA THERAPY MARKET, BY COUNTRY
    • 10.3.2. GERMANY
      • 10.3.2.1. GERMANY PLASMA THERAPY MARKET OVERVIEW
      • 10.3.2.2. GERMANY PLASMA THERAPY MARKET, BY TYPE
      • 10.3.2.3. GERMANY PLASMA THERAPY MARKET, BY SOURCE
      • 10.3.2.4. GERMANY PLASMA THERAPY MARKET, BY APPLICATION
      • 10.3.2.5. GERMANY PLASMA THERAPY MARKET, BY END USER
    • 10.3.3. U.K.
      • 10.3.3.1. U.K. PLASMA THERAPY MARKET OVERVIEW
      • 10.3.3.2. U.K. PLASMA THERAPY MARKET, BY TYPE
      • 10.3.3.3. U.K. PLASMA THERAPY MARKET, BY SOURCE
      • 10.3.3.4. U.K. PLASMA THERAPY MARKET, BY APPLICATION
      • 10.3.3.5. U.K. PLASMA THERAPY MARKET, BY END USER
    • 10.3.4. FRANCE
      • 10.3.4.1. FRANCE PLASMA THERAPY MARKET OVERVIEW
      • 10.3.4.2. FRANCE PLASMA THERAPY MARKET, BY TYPE
      • 10.3.4.3. FRANCE PLASMA THERAPY MARKET, BY SOURCE
      • 10.3.4.4. FRANCE PLASMA THERAPY MARKET, BY APPLICATION
      • 10.3.4.5. FRANCE PLASMA THERAPY MARKET, BY END USER
    • 10.3.5. SPAIN
      • 10.3.5.1. SPAIN PLASMA THERAPY MARKET OVERVIEW
      • 10.3.5.2. SPAIN PLASMA THERAPY MARKET, BY TYPE
      • 10.3.5.3. SPAIN PLASMA THERAPY MARKET, BY SOURCE
      • 10.3.5.4. SPAIN PLASMA THERAPY MARKET, BY APPLICATION
      • 10.3.5.5. SPAIN PLASMA THERAPY MARKET, BY END USER
    • 10.3.6. ITALY
      • 10.3.6.1. ITALY PLASMA THERAPY MARKET OVERVIEW
      • 10.3.6.2. ITALY PLASMA THERAPY MARKET, BY TYPE
      • 10.3.6.3. ITALY PLASMA THERAPY MARKET, BY SOURCE
      • 10.3.6.4. ITALY PLASMA THERAPY MARKET, BY APPLICATION
      • 10.3.6.5. ITALY PLASMA THERAPY MARKET, BY END USER
    • 10.3.7. REST OF EUROPE (ROE)
      • 10.3.7.1. REST OF EUROPE PLASMA THERAPY MARKET OVERVIEW
      • 10.3.7.2. REST OF EUROPE PLASMA THERAPY MARKET, BY TYPE
      • 10.3.7.3. REST OF EUROPE PLASMA THERAPY MARKET, BY SOURCE
      • 10.3.7.4. REST OF EUROPE PLASMA THERAPY MARKET, BY APPLICATION
      • 10.3.7.5. REST OF EUROPE PLASMA THERAPY MARKET, BY END USER
  • 10.4. ASIA-PACIFIC
    • 10.4.1. INTRODUCTION
      • 10.4.1.1. COMPETITION IN ASIA-PACIFIC PLASMA THERAPY MARKET
      • 10.4.1.2. NEAR TERM, MID TERM, AND LONG TERM GROWTH OF PLASMA THERAPY MARKET IN APAC
    • 10.4.2. ASIA-PACIFIC PLASMA THERAPY MARKET, BY TYPE
    • 10.4.3. ASIA-PACIFIC PLASMA THERAPY MARKET, BY SOURCE
    • 10.4.4. ASIA-PACIFIC PLASMA THERAPY MARKET, BY APPLICATION
    • 10.4.5. ASIA-PACIFIC PLASMA THERAPY MARKET, BY END USER
    • 10.4.6. ASIA-PACIFIC PLASMA THERAPY MARKET, BY COUNTRY
    • 10.4.7. JAPAN
      • 10.4.7.1. OVERVIEW
      • 10.4.7.2. JAPAN PLASMA THERAPY MARKET, BY TYPE
      • 10.4.7.3. JAPAN PLASMA THERAPY MARKET, BY SOURCE
      • 10.4.7.4. JAPAN PLASMA THERAPY MARKET, BY APPLICATION
      • 10.4.7.5. JAPAN PLASMA THERAPY MARKET, BY END USER
    • 10.4.8. CHINA
      • 10.4.8.1. OVERVIEW
      • 10.4.8.2. CHINA PLASMA THERAPY MARKET, BY TYPE
      • 10.4.8.3. CHINA PLASMA THERAPY MARKET, BY SOURCE
      • 10.4.8.4. CHINA PLASMA THERAPY MARKET, BY APPLICATION
      • 10.4.8.5. CHINA PLASMA THERAPY MARKET, BY END USER
    • 10.4.9. AUSTRALIA
      • 10.4.9.1. OVERVIEW
      • 10.4.9.2. AUSTRALIA PLASMA THERAPY MARKET, BY TYPE
      • 10.4.9.3. AUSTRALIA PLASMA THERAPY MARKET, BY SOURCE
      • 10.4.9.4. AUSTRALIA PLASMA THERAPY MARKET, BY APPLICATION
      • 10.4.9.5. AUSTRALIA PLASMA THERAPY MARKET, BY END USER
    • 10.4.10. INDIA
      • 10.4.10.1. OVERVIEW
      • 10.4.10.2. INDIA PLASMA THERAPY MARKET, BY TYPE
      • 10.4.10.3. INDIA PLASMA THERAPY MARKET, BY SOURCE
      • 10.4.10.4. INDIA PLASMA THERAPY MARKET, BY APPLICATION
      • 10.4.10.5. INDIA PLASMA THERAPY MARKET, BY END USER
    • 10.4.11. REPUBLIC OF KOREA
      • 10.4.11.1. OVERVIEW
      • 10.4.11.2. REPUBLIC OF KOREA PLASMA THERAPY MARKET, BY TYPE
      • 10.4.11.3. REPUBLIC OF KOREA PLASMA THERAPY MARKET, BY SOURCE
      • 10.4.11.4. REPUBLIC OF KOREA PLASMA THERAPY MARKET, BY APPLICATION
      • 10.4.11.5. REPUBLIC OF KOREA PLASMA THERAPY MARKET, BY END USER
    • 10.4.12. REST OF ASIA-PACIFIC
      • 10.4.12.1. OVERVIEW
      • 10.4.12.2. REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY TYPE
      • 10.4.12.3. REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY SOURCE
      • 10.4.12.4. REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY APPLICATION
      • 10.4.12.5. REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY END USER
  • 10.5. REST OF THE WORLD (ROW)
    • 10.5.1. ROW PLASMA THERAPY MARKET, BY TYPE
    • 10.5.2. ROW PLASMA THERAPY MARKET, BY SOURCE
    • 10.5.3. ROW PLASMA THERAPY MARKET, BY APPLICATION
    • 10.5.4. ROW PLASMA THERAPY MARKET, BY END USER

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET SHARE ANALYSIS
  • 11.3. COMPETITIVE SITUATION AND TRENDS
    • 11.3.1. REGULATORY APPROVALS
    • 11.3.2. EXPANSIONS
    • 11.3.3. AGREEMENTS
    • 11.3.4. NEW PRODUCT LAUNCHES
    • 11.3.5. ACQUISITIONS

12. COMPANY PROFILE (Overview, Financial*, Products & Services, Strategy, and Developments)

  • 12.1. BIOLIFE PLASMA SERVICES
  • 12.2. CAMBRYN BIOLOGICS LLC
  • 12.3. BIOTEST
  • 12.4. CSL LTD.
  • 12.5. GRIFOLS INTERNATIONAL S.A.
  • 12.6. KEDRION S.P.A.
  • 12.7. LFB SA
  • 12.8. BIO PRODUCT LABORATORY LTD. (BPL)
  • 12.9. CHINA BIOLOGIC PRODUCTS, INC.
  • 12.10. OCTAPHARMA

*Details might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.4. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: INDICATIONS FOR THERAPEUTIC USE OF PLASMA - FIRST LINE THERAPY
  • TABLE 2: INDICATIONS FOR THERAPEUTIC USE OF PLASMA - SECOND LINE THERAPY
  • TABLE 3: PLASMA THERAPY MARKET BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 4: PURE PRP MARKET, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 5: LEUKOCYTE-RICH PRP MARKET, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 6: PURE PLATELET-RICH FIBRIN MARKET, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 7: LEUKOCYTE-RICH FIBRIN MARKET, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 8: PLASMA THERAPY MARKET , BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 9: AUTOLOGOUS SOURCE MARKET , BY REGION, 2014-2021 (USD MILLION)
  • TABLE 10: ALLOGENIC SOURCE MARKET , BY REGION, 2014-2021 (USD MILLION)
  • TABLE 11: PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 12: PLASMA THERAPY MARKET FOR ORTHOPEDIC, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 13: PLASMA THERAPY MARKET FOR ORTHOPEDIC APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 14: PLASMA THERAPY MARKET FOR ARTHRITIS APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 15: PLASMA THERA[Y MARKET FOR CHRONIC TENDINITIS APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 16: PLASMA THERAPY MARKET FOR BONE REPAIR & REGENERATION APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: PLASMA THERAPY MARKET FOR DERMATOLOGY APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 18: PLASMA THERAPY MARKET FOR ANDROGENIC ALOPECIA APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 19: PLASMA THERAPY MARKET FOR PLASTIC SURGERY APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: PLASMA THERAPY MARKET FOR CARDIAC MUSCLE INJURY APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 21: PLASMA THERAPY MARKET FOR DENTAL APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 22: PLASMA THERAPY MARKET FOR NERVE INJURY APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 24: PLASMA THERAPY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 25: PLASMA THERAPY MARKET FOR RESEARCH INSTITUTES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 26: NORTH AMERICA PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 27: NORTH AMERICA PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 28: NORTH AMERICA PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 29: NORTH AMERICA PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 30: NORTH AMERICA PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 31: NORTH AMERICA PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 32: NORTH AMERICA PLASMA THERAPY MARKET, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 33: U.S. PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 34: U.S. PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 35: U.S. PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 36: U.S. PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 37: U.S. PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 38: U.S. PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 39: CANADA PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 40: CANADA PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 41: CANADA PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 42: CANADA PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 43: CANADA PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 44: CANADA PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 45: EUROPE PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 46: EUROPE PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 47: EUROPE PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 48: EUROPE PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 49: EUROPE PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 50: EUROPE PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 51: EUROPE PLASMA THERAPY MARKET, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 52: GERMANY PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 53: GERMANY PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 54: GERMANY PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 55: GERMANY PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 56: GERMANY PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 57: GERMANY PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 58: U.K. PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 59: U.K. PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 60: U.K. PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 61: U.K. PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 62: U.K. PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 63: U.K. PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 64: FRANCE PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 65: FRANCE PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 66: FRANCE PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 67: FRANCE PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 68: FRANCE PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 69: FRANCE PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 70: SPAIN PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 71: SPAIN PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 72: SPAIN PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 73: SPAIN PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 74: SPAIN PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 75: SPAIN PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 76: ITALY PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 77: ITALY PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 78: ITALY PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 79: ITALY PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 80: ITALY PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 81: ITALY PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 82: REST OF EUROPE PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 83: REST OF EUROPE PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 84: REST OF EUROPE PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 85: REST OF EUROPE PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 86: REST OF EUROPE PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 87: REST OF EUROPE PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 88: ASIA-PACIFIC PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 89: ASIA-PACIFIC PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 90: ASIA-PACIFIC PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 91: ASIA-PACIFIC PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 92: ASIA-PACIFIC PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 93: ASIA-PACIFIC PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 94: ASIA-PACIFIC PLASMA THERAPY MARKET, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 95: JAPAN PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 96: JAPAN: PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 97: JAPAN PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 98: JAPAN PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 99: JAPAN PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 100: JAPAN PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 101: CHINA PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 102: CHINA PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 103: CHINA PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 104: CHINA PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 105: CHINA PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 106: CHINA PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 107: AUSTRALIA PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 108: AUSTRALIA PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 109: AUSTRALIA PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 110: AUSTRALIA PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 111: AUSTRALIA PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 112: AUSTRALIA PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 113: INDIA PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 114: INDIA PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 115: INDIA PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 116: INDIA PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 117: INDIA PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 118: INDIA PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 119: REPUBLIC OF KOREA PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 120: REPUBLIC OF KOREA PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 121: REPUBLIC OF KOREA PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 122: REPUBLIC OF KOREA PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 123: REPUBLIC OF KOREA PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 124: REPUBLIC OF KOREA PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 125: REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 126: REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 127: REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 128: REST OF ASIA-PACIFIC PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 129: REST OF ASIA-PACIFIC PLASMA THERAPY MARKET IN DERMATOLOGY, 2014-2021 (USD MILLION)
  • TABLE 130: REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 131: ROW PLASMA THERAPY MARKET, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 132: ROW PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • TABLE 133: ROW PLASMA THERAPY MARKET, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 134: ROW PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 135: ROW PLASMA THERAPY MARKET IN DERMARTOLOGY, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 136: ROW PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 137: REGULATORY APPROVALS, 2014-2016
  • TABLE 138: EXPANSIONS, 2013-2016
  • TABLE 139: AGREEMENTS, 2013-2016
  • TABLE 140: NEW PRODUCT LAUNCHES, 2013-2014
  • TABLE 141: ACQUISITIONS, 2013-2016

LIST OF FIGURES

  • FIGURE 1: GLOBAL PLASMA THERAPY MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, & REGION
  • FIGURE 4: BOTTOM-UP APPROACH
  • FIGURE 5: TOP-DOWN APPROACH
  • FIGURE 6: RESEARCH METHODOLOGY: DATA TRIANGULATION
  • FIGURE 7: LEUKOCYTE-RICH PRP PROJECTED TO BE THE FASTEST-GROWING SEGMENT IN THE PLASMA THERAPY MARKET
  • FIGURE 8: THE AUTOLOGOUS SEGMENT ESTIMATED TO DOMINATE THE PLASMA THERAPY MARKET IN 2016
  • FIGURE 9: DERMATOLOGY ESTIMATED TO BE THE FASTEST-GROWING APPLICATION OF THE PLASMA THERAPY MARKET
  • FIGURE 10: THE HOSPITALS & CLINICS SEGMENT ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE IN 2016
  • FIGURE 11: EUROPE ESTIMATED TO GROW AT THE HIGHEST CAGR IN THE PLASMA THERAPY MARKET
  • FIGURE 12: GLOBAL PLASMA THERAPY MARKET TO WITNESS MODERATE GROWTH DURING THE FORECAST PERIOD
  • FIGURE 13: THE PURE PRP SEGMENT ESTIMATED TO LEAD THE GLOBAL PLASMA THERAPY MARKET IN 2016
  • FIGURE 14: THE PLASMA THERAPY MARKET IN EUROPE TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 15: INCREASING USE OF PRP THERAPY IN SPORTS INJURIES TO PROPEL THE GROWTH OF THE PLASMA THERAPY MARKET
  • FIGURE 16: PLASMA THERAPY MARKET SEGMENTATION, BY TYPE
  • FIGURE 17: LEUKOCYTE-RICH PRP TO FORM THE LARGEST TYPE SEGMENT IN 2016
  • FIGURE 18: NORTH AMERICA TO DOMINATE THE PURE PRP MARKET IN 2016
  • FIGURE 19: NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE LEUKOCYTE-RICH PRP MARKET IN 2016
  • FIGURE 20: NORTH AMERICA TO COMMAND THE LARGEST SHARE OF PURE PLATELET-RICH FIBRIN MARKET IN 2016
  • FIGURE 21: NORTH AMERICA TO DOMINATE THE LEUKOCYTE-RICH FIBRIN MARKET IN 2016
  • FIGURE 22: PLASMA THERAPY MARKET SEGMENTATION, BY SOURCE
  • FIGURE 23: ALLOGENIC SOURCE TO BE THE LARGEST SEGMENT IN 2016
  • FIGURE 24: NORTH AMERICA TO LEAD THE AUTOLOGOUS SOURCE MARKET IN 2016
  • FIGURE 25: NORTH AMERICA TO LEAD THE ALLOGENIC SOURCE MARKET IN 2016
  • FIGURE 26: PLASMA THERAPY MARKET SEGMENTATION, BY APPLICATION
  • FIGURE 27: DERMATOLOGY SEGMENT TO DOMINATE THE PLASMA THERAPY APPLICATIONS MARKET IN 2016 59  
  • FIGURE 28: ARTHRITIS TREATMENT TO DOMINATE THE PLASMA THERAPY MARKET FOR ORTHOPEDIC IN 2016
  • FIGURE 29: NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE PLASMA THERAPY MARKET FOR ORTHOPEDIC APPLICATION IN 2016
  • FIGURE 30: NORTH AMERICA TO DOMINATE THE PLASMA THERAPY MARKET FOR DERMATOLOGY APPLICATION IN 2016
  • FIGURE 31: ANDROGENIC ALOPECIA APPLICATION IN 2016
  • FIGURE 32: PLASTIC SURGERY IN 2016
  • FIGURE 33: NORTH AMERICA TO DOMINATE THE PLASMA THERAPY MARKET FOR CARDIAC MUSCLE INJURY APPLICATION IN 2016
  • FIGURE 34: NORTH AMERICA TO DOMINATE THE PLASMA THERAPY MARKET FOR DENTAL APPLICATION IN 2016
  • FIGURE 35: NORTH AMERICA TO DOMINATE THE PLASMA THERAPY MARKET FOR NERVE INJURY APPLICATION IN 2016
  • FIGURE 36: PLASMA THERAPY MARKET SEGMENTATION, BY END USER
  • FIGURE 37: PLASMA THERAPY MARKET SIZE, BY END USER, 2016 & 2021 (USD MILLION)
  • FIGURE 38: HOSPITALS & CLINICS OVERVIEW
  • FIGURE 39: NORTH AMERICA TO DOMINATE THE PLASMA THERAPY MARKET FOR HOSPITALS & CLINICS IN 2016
  • FIGURE 40: NORTH AMERICA TO DOMINATE THE PLASMA THERAPY MARKET FOR RESEARCH INSTITUTES BETWEEN 2016 AND 2021
  • FIGURE 41: GEOGRAPHIC SNAPSHOT (2016-2021) - THE MARKET IN THE U.K. EXPECTED TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 42: THE LEUKOCYTE-RICH PRP SEGMENT HAS HIGH GROWTH POTENTIAL ACROSS ALL REGIONS
  • FIGURE 43: NORTH AMERICA PLASMA THERAPY MARKET SNAPSHOT
  • FIGURE 44: NORTH AMERICA PLASMA THERAPY MARKET, BY TYPE, 2016 (USD MILLION)
  • FIGURE 45: NORTH AMERICA PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • FIGURE 46: NORTH AMERICA PLASMA THERAPY MARKET, BY APPLICATION, 2016 & 2021 (USD MILLION)
  • FIGURE 47: NORTH AMERICA PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2016 & 2021 (USD MILLION)
  • FIGURE 48: NORTH AMERICA PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2016 & 2021 (USD MILLION)
  • FIGURE 49: NORTH AMERICA PLASMA THERAPY MARKET, BY END-USER, 2014-2021 (USD MILLION)
  • FIGURE 50: NORTH AMERICA PLASMA THERAPY MARKET, BY COUNTRY, 2016 & 2021 (USD MILLION)
  • FIGURE 51: U.S. PLASMA THERAPY MARKET OVERVIEW, 2016 & 2021
  • FIGURE 52: CANADA PLASMA THERAPY MARKET OVERVIEW
  • FIGURE 53: EUROPE PLASMA THERAPY MARKET SNAPSHOT - GERMANY IS THE MOST LUCRATIVE MARKET
  • FIGURE 54: EUROPE PLASMA THERAPY MARKET, BY TYPE, 2016 (USD MILLION)
  • FIGURE 55: EUROPE PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION) 104  
  • FIGURE 56: EUROPE PLASMA THERAPY MARKET, BY APPLICATION, 2016 & 2021 (USD MILLION)
  • FIGURE 57: EUROPE PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2016 & 2021 (USD MILLION)
  • FIGURE 58: EUROPE PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2016 & 2021 (USD MILLION)
  • FIGURE 59: EUROPE PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • FIGURE 60: EUROPE PLASMA THERAPY MARKET, BY COUNTRY, 2016 & 2021 (USD MILLION)
  • FIGURE 61: GERMANY PLASMA THERAPY MARKET OVERVIEW, 2016 & 2021
  • FIGURE 62: U.K. PLASMA THERAPY MARKET OVERVIEW, 2016 & 2021
  • FIGURE 63: FRANCE PLASMA THERAPY MARKET OVERVIEW, 2016 & 2021
  • FIGURE 64: SPAIN PLASMA THERAPY MARKET OVERVIEW, 2016 & 2021
  • FIGURE 65: ITALY PLASMA THERAPY MARKET OVERVIEW, 2016 & 2021
  • FIGURE 66: REST OF EUROPE PLASMA THERAPY MARKET OVERVIEW, 2016 & 2021
  • FIGURE 67: APAC PLASMA THERAPY MARKET SNAPSHOT - CHINA IS THE MOST LUCRATIVE MARKET
  • FIGURE 68: APAC PLASMA THERAPY MARKET , BY TYPE, 2016 (USD MILLION)
  • FIGURE 69: APAC PLASMA THERAPY MARKET, BY SOURCE, 2014-2021 (USD MILLION)
  • FIGURE 70: APAC PLASMA THERAPY MARKET , BY APPLICATION, 2016 & 2021 (USD MILLION)
  • FIGURE 71: APAC PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2016 & 2021 (USD MILLION)
  • FIGURE 72: APAC PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2016 & 2021 (USD MILLION)
  • FIGURE 73: APAC PLASMA THERAPY MARKET , BY END USER, 2014-2021 (USD MILLION)
  • FIGURE 74: APAC PLASMA THERAPY MARKET , BY COUNTRY, 2016 & 2021 (USD MILLION)
  • FIGURE 75: JAPAN PLASMA THERAPY MARKET OVERVIEW,2016 & 2021
  • FIGURE 76: CHINA PLASMA THERAPY MARKET OVERVIEW,2016 & 2021
  • FIGURE 77: AUSTRALIA PLASMA THERAPY MARKET OVERVIEW,2016 & 2021
  • FIGURE 78: INDIA PLASMA THERAPY MARKET OVERVIEW,2016 & 2021
  • FIGURE 79: REPUBLIC OF KOREA PLASMA THERAPY MARKET OVERVIEW,2016 & 2021
  • FIGURE 80: REST OF ASIA-PACIFIC PLASMA THERAPY MARKET OVERVIEW, 2016 & 2021
  • FIGURE 81: PURE PRP ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE IN THE ROW PLASMA THERAPY MARKET IN 2016
  • FIGURE 82: ROW PLASMA THERAPY MARKET OVERVIEW,2016
  • FIGURE 83: ROW PLASMA THERAPY MARKET ,BY SOURCE ,2014 TO 2021 (USD MILLION)
  • FIGURE 84: ROW PLASMA THERAPY MARKET ,BY APPLICATION , 2016 & 2021 (USD MILLION)
  • FIGURE 85: ROW PLASMA THERAPY MARKET IN ORTHOPEDIC, BY TYPE, 2016-2021 (USD MILLION)
  • FIGURE 86: ROW PLASMA THERAPY MARKET IN DERMATOLOGY, BY TYPE, 2016 & 2021 (USD MILLION)
  • FIGURE 87: ROW PLASMA THERAPY MARKET, BY END USER, 2014-2021 (USD MILLION)
  • FIGURE 88: LEADING MARKET PLAYERS ADOPTED ORGANIC AND INORGANIC GROWTH STRATEGIES IN THE PAST FOUR YEARS (2013-2016)
  • FIGURE 89: GLOBAL PLASMA THERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015 167  
  • FIGURE 90: BATTLE FOR MARKET SHARE: ACQUISITIONS, EXPANSIONS, AND PARTNERSHIPS ARE KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS
  • FIGURE 91: BAXALTA INC: COMPANY SNAPSHOT
  • FIGURE 92: BIOTEST: COMPANY SNAPSHOT
  • FIGURE 93: CSL LTD.: COMPANY SNAPSHOT
  • FIGURE 94: GRIFOLS INTERNATIONAL S.A.: COMPANY SNAPSHOT
  • FIGURE 95: KEDRION S.P.A.: COMPANY SNAPSHOT
  • FIGURE 96: LFB SA: COMPANY SNAPSHOT
  • FIGURE 97: CHINA BIOLOGIC PRODUCTS, INC.: COMPANY SNAPSHOT
  • FIGURE 98: OCTAPHARMA: COMPANY SNAPSHOT
Back to Top